105391-70-6

Basic information

• Product Name: 5-BROMO-6-FLUORO-1H-INDAZOLE
• Synonyms: 5-BROMO-6-FLUORO-1H-INDAZOLE;1H-Indazole, 5-bromo-6-fluoro-;5-BroMo-6-fluoro-1H-;5-BROMO-6-FLUOROINDAZOLE
• CAS NO: 105391-70-6
• Molecular Formula: C7H4BrFN2
• Molecular Weight: 215.02
• Product Categories: Indazoles
• Mol File: 105391-70-6.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 332.199 °C at 760 mmHg
• Flash Point: 154.709 °C
• Appearance: /
• Density: 1.861
• Refractive Index: 1.693
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.95±0.40(Predicted)
• CAS DataBase Reference: 5-BROMO-6-FLUORO-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-6-FLUORO-1H-INDAZOLE(105391-70-6)
• EPA Substance Registry System: 5-BROMO-6-FLUORO-1H-INDAZOLE(105391-70-6)

Safety Data

• Hazardous Substances Data: 105391-70-6(Hazardous Substances Data)

Usage

Uses

5-Bromo-6-fluoro-1H-indazole is used for optimization and biological evaluation of [(trifluoromethyl)phenyl]indazoles as TRPA1 antagonists.

InChI:InChI=1/C7H4BrFN2/c8-5-1-4-3-10-11-7(4)2-6(5)9/h1-3H,(H,10,11)

Upstream product

• 633335-80-5 N-(4-bromo-5-fluoro-2-methylphenyl)acetamide 
• 367-29-3 3-fluoro-6-methylaniline 
• 366-49-4 5’-fluoro-2’-methylacetanilide 
• 557-21-1 zinc(II) cyanide 
• 633335-81-6 1-(5-bromo-6-fluoro-1H-indazol-1-yl)ethan-1-one 
• 52723-82-7 4-bromo-5-fluoro-2-methylaniline 

Downstream Products

• 1126425-15-7 6-fluoro-1H-indazole-5-carbaldehyde 
• 633327-11-4 6-fluoro-1H-indazole-5-carbonitrile 
• 1608480-98-3 5-(benzylthio)-6-fluoro-1-(2-iodobenzyl)-1H-indazole 
• 1608480-99-4 6-fluoro-1-(2-iodobenzyl)-1H-indazole-5-sulfonyl chloride 
• 1608481-00-0 N-(2,4-dimethoxybenzyl)-6-fluoro-1-(2-iodobenzyl)-N-(1,2,4-thiadiazol-5-yl)-1H-indazole-5-sulfonamide 
• 1608479-65-7 (E)-1-(2-(3-aminoprop-1-en-1-yl)benzyl)-6-fluoro-N-(1,2,4-thiadiazol-5-yl)-1H-indazole-5-sulfonamide trifluoroacetate 
• 1608481-03-3 N-(2,4-dimethoxybenzyl)-6-fluoro-N-(1,2,4-thiadiazole-5-yl)-1H-indazole-5-sulfonamide 
• 1608480-95-0 5-(benzylthio)-6-fluoro-1H-indazole 
• 1613505-13-7 6-fluoro-5-(2-(trifluoromethyl)phenyl)-1H-indazole 
• 1613504-89-4 C₁₉H₁₆F₄N₂O 

Relevant articles and documents

Compounds and their use in treatment on hepatitis B

The invention provides compounds, a pharmaceutical composition containing the compounds and an application of the compounds. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, nitric oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The compound provided by the invention can interfere with the shell assembly process of hepatitis B virus, thereby inhibiting hepatitis B virus replication. Moreover, the compound has good absorption, relatively high biological activity and availability and low toxicity, particularly has relatively strong stability in vivo, is not easy to decompose and has long drug effect time, so that an effect of treating hepatitis B is achieved and the compound has a goodapplication prospect.

3-(1H-PYRROLO[2,3-C]PYRIDIN-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-INDOL-2-YL)-1H-INDAZOLES AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.